Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug

Source: CNBC | Published: March 10, 2025, 11:30 a.m.

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

Read Original Article Back to News List

Related News

Trump's approval rating on the economy drops to lowest of his presidential career, CNBC Survey finds

18 hours, 40 minutes ago

I'm a dietitian who practices 'stress-free eating': These are the foods I eat every week—'I try for a balanced plate'

19 hours, 16 minutes ago

This fund is designed to help investors withstand wild market swings

19 hours, 16 minutes ago

White House claims letter to Harvard with demands was an 'unauthorized' mistake: NYT

19 hours, 42 minutes ago

Look inside: We spent $64 million turning an old Virginia prison into an apartment complex— 'it's important to preserve history'

20 hours, 16 minutes ago